Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
Cuprina meets Nasdaq listing requirements again
Cuprina has again met the Nasdaq Capital Market’s requirements after its share price rose above the minimum bid price of $1.00. Nasdaq staff informed the hearing panel, which led to the delisting hearing scheduled for July 7 being cancelled and the common shares continuing to trade under the ticker CUPR. The stock is trading at $2.41, remains well below its 52-week high, and the company is rated as financially weak. » Plus sur de.investing.com
Cuprina requests hearing against NASDAQ delisting
Cuprina has filed an objection with the Nasdaq Hearings Panel against the announced termination of its listing after the stock traded below the $1.00 minimum price for more than 30 trading days. The company recently completed a reverse stock split; the filing seeks to suspend trading and the submission of Form 25-NSE until a decision is made. Despite a 91% decline over the past year, the stock rose 53% last week, but analyst data highlight large cash outflows, a negative gross margin and a weak financial position as key risks. » Plus sur de.investing.com
Cuprina Holdings calls annual general meeting for May 14, 2026
Cuprina Holdings has announced the convening of its annual general meeting for May 14, 2026, and filed the related materials with the SEC. Shareholders will receive a proxy statement and proxy card; on the agenda are, among other items, the "Cuprina 2026 Employee Incentive Plan" and a proposal to amend the bylaws. The company, signed by CEO David Quek Yong Qi, has a market capitalization of $13.5 billion, a share return of 92% last year, but most recently reported a loss of $2.30 per share; analysts expect earnings of $5.75 per share for 2026. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | déc. 2025 | |
|---|---|---|
| Chiffre d'affaires | 17,75 k | - |
| Bénéfice brut | -10,93 k | - |
| Bénéfice net | -1,78 M | - |
| EBITDA | -1,86 M | - |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 6,97 M € |
Nombre d'actions | 2,68 M |
Plus haut/bas sur 52 semaines | 16,92 € - 1,52 € |
| Dividendes | Non |
Bêta | -0,38 |
Ratio P/E | -2,08 |
Ratio PEG | -0,02 |
Ratio P/B | 1,94 |
Ratio P/S | 206,16 |
Profil de l'entreprise
Cuprina Holdings (Cayman) Limited ist ein in Singapur ansässiges Biomedizin- und Biotechnologieunternehmen, das sich der Entwicklung und Vermarktung innovativer Produkte für die Behandlung chronischer Wunden widmet. Das Unternehmen produziert und vertreibt sterile Schmeißfliegenlarven-Bio-Dressing-Produkte in medizinischer Qualität unter der Marke MEDIFLY, die als biologisches Debridement-Tool für chronische Wunden verwendet werden. Darüber hinaus ist Cuprina in den Bereichen Gesundheit und Schönheit tätig und bietet kosmetische Produkte an.
| Nom | CUPRINA H. (KY) LTD |
| PDG | Yong Qi Quek |
| Site web | |
| Introduction en bourse | 10/04/2025 |
| Employés | 10 |
Découvrir des actifs
Les actionnaires de CUPRINA H. (KY) LTD investissent également dans les actifs suivants

